Expression and prognostic significance of ELL-associated factor 2 in human prostate cancer
International Urology and Nephrology, ISSN: 1573-2584, Vol: 48, Issue: 5, Page: 695-700
2016
- 10Citations
- 15Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations10
- Citation Indexes10
- 10
- CrossRef2
- Captures15
- Readers15
- 15
Article Description
Purpose: ELL-associated factor 2 (EAF2) is an androgen-regulated tumor suppressor in the prostate. The purpose of this study was to investigate the expression of EAF2 protein in human prostate cancer specimens along with BPH specimens as a control, and to evaluate potential association of EAF2 expression with clinical characteristics and overall survival of the prostate cancer patients. Methods: The expression of EAF2 was evaluated in 44 prostate cancer and 23 BPH tissue specimens using immunohistochemistry. The relationships of EAF2 expression with clinical characteristics and overall survival rates were analyzed by Chi-square test and Kaplan–Meier method. Results: The immunostaining intensity of EAF2 in BPH specimens was significantly higher than that in prostate cancer (p < 0.05). EAF2 expression decreased significantly in high-grade and advanced-stage human prostate tumors and inversely correlated with PSA level, Gleason scores, bone metastasis and tumor stage. Importantly, loss of EAF2 expression was associated with a significant decrease in patient survival. Conclusion: Expression of EAF2 is decreased in prostate carcinogenesis, and EAF2 loss is associated with high-risk patients and poor survival.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84958774427&origin=inward; http://dx.doi.org/10.1007/s11255-015-1210-y; http://www.ncbi.nlm.nih.gov/pubmed/26895851; http://link.springer.com/10.1007/s11255-015-1210-y; https://dx.doi.org/10.1007/s11255-015-1210-y; https://link.springer.com/article/10.1007/s11255-015-1210-y; http://link.springer.com/content/pdf/10.1007/s11255-015-1210-y; https://link.springer.com/content/pdf/10.1007/s11255-015-1210-y.pdf; http://link.springer.com/content/pdf/10.1007/s11255-015-1210-y.pdf; https://link.springer.com/content/pdf/10.1007%2Fs11255-015-1210-y.pdf; http://link.springer.com/article/10.1007/s11255-015-1210-y/fulltext.html; http://link.springer.com/article/10.1007%2Fs11255-015-1210-y
Springer Science and Business Media LLC
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know